Join Growin Stock Community!

醣聯4168.TW Overview

TW StockBiotech. & Medical
(No presentation for 4168)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

醣聯（4168）Overall Performance

醣聯（4168）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

醣聯（4168） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

醣聯（4168）Key Information

醣聯（4168）Profile

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.

醣聯（4168）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.37%
Net Margin
-593.95%
Revenue Growth (YoY)
196.37%
Profit Growth (YoY)
245.23%
3-Year Revenue Growth
-36.41%
3-Year Profit Growth
-34.44%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
64.37%
Net Margin
-593.95%
Revenue Growth (YoY)
196.37%
Profit Growth (YoY)
245.23%
3-Year Revenue Growth
-36.41%
3-Year Profit Growth
-34.44%
default symbol

4168

醣聯

24.80D

-2.42%

(-0.02)

  • When is 4168's latest earnings report released?

    The most recent financial report for 醣聯 (4168) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4168's short-term business performance and financial health. For the latest updates on 4168's earnings releases, visit this page regularly.

  • What is the operating profit of 4168?

    According to the latest financial report, 醣聯 (4168) reported an Operating Profit of -70.2M with an Operating Margin of -1,822.48% this period, representing a decline of 40.3% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4168's revenue growth?

    In the latest financial report, 醣聯 (4168) announced revenue of 3.85M, with a Year-Over-Year growth rate of 75.89%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4168 have?

    At the end of the period, 醣聯 (4168) held Total Cash and Cash Equivalents of 528.48M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4168 go with three margins increasing?

    In the latest report, 醣聯 (4168) did not achieve the “three margins increasing” benchmark, with a gross margin of 65.42%%, operating margin of -1,822.48%%, and net margin of -1,534.35%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4168's profit trajectory and future growth potential.

  • Is 4168's EPS continuing to grow?

    According to the past four quarterly reports, 醣聯 (4168)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4168?

    醣聯 (4168)'s Free Cash Flow (FCF) for the period is -540.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 5,925.04% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.